- Home
- VOR vs FDMT Comparison
VOR vs FDMT Comparison
Compare VOR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- FDMT
- Stock Information
- Founded
- VOR 2015
- FDMT 2013
- Country
- VOR United States
- FDMT United States
- Employees
- VOR N/A
- FDMT N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- VOR Health Care
- FDMT Health Care
- Exchange
- VOR Nasdaq
- FDMT Nasdaq
- Market Cap
- VOR 202.4M
- FDMT 192.2M
- IPO Year
- VOR 2021
- FDMT 2020
- Fundamental
- Price
- VOR $2.30
- FDMT $4.38
- Analyst Decision
- VOR Buy
- FDMT Buy
- Analyst Count
- VOR 7
- FDMT 10
- Target Price
- VOR $3.77
- FDMT $32.33
- AVG Volume (30 Days)
- VOR 47.3M
- FDMT 410.7K
- Earning Date
- VOR 08-07-2025
- FDMT 08-07-2025
- Dividend Yield
- VOR N/A
- FDMT N/A
- EPS Growth
- VOR N/A
- FDMT N/A
- EPS
- VOR N/A
- FDMT N/A
- Revenue
- VOR N/A
- FDMT $23,000.00
- Revenue This Year
- VOR N/A
- FDMT $13,048.65
- Revenue Next Year
- VOR N/A
- FDMT N/A
- P/E Ratio
- VOR N/A
- FDMT N/A
- Revenue Growth
- VOR N/A
- FDMT N/A
- 52 Week Low
- VOR $0.13
- FDMT $2.24
- 52 Week High
- VOR $3.29
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- VOR 78.77
- FDMT 56.61
- Support Level
- VOR $2.25
- FDMT $4.23
- Resistance Level
- VOR $3.29
- FDMT $4.50
- Average True Range (ATR)
- VOR 0.52
- FDMT 0.26
- MACD
- VOR 0.18
- FDMT 0.01
- Stochastic Oscillator
- VOR 82.52
- FDMT 85.37
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.